Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis

References

• American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society, 2011
   Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
   PubMed Web of Science ®Google Scholar
• Seidler AM, Pennie ML, Veledar E, et al. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)–Medicare data. Arch Dermatol 2010;146:249-56
   PubMedGoogle Scholar
• Taneja C, Edelsberg J, Penrod JR, et al. Epidemiology of advanced melanoma: findings from a large US health insurance database. Presented at Perspectives in Melanoma XV, September 16–17, 2011; New York, NY, USA
   Google Scholar
• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81
   PubMed Web of Science ®Google Scholar
• Melanoma information page. Cancer Council Australia, 2012. http://www.cancer.org.au/aboutcancer/cancertypes/melanoma.htm. Accessed 27 January 27, 2012
   Google Scholar
• Bakos LÃ. Melanoma cutâneo: estudos de base populacional no Brasil. Anais Brasileiros de Dermatologia 2006;81:402
   Google Scholar
• Surveillance, Epidemiology and End Results (SEER) Stat Fact Sheets: Melanoma of the Skin. National Cancer Institute, Bethesda, 2012. http://seer.cancer.gov/statfacts/html/melan.html. Accessed July 13, 2012
   Google Scholar
• Coit DG, Andtbacka R, Anker CJ, et al. Melanoma. J Natl Compr Canc Netw 2012;10:366-400
   PubMed Web of Science ®Google Scholar
• Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34
   PubMed Web of Science ®Google Scholar
• Dequen P, Lorigan P, Jansen JP, et al. Systematic Review and Network Meta-Analysis of Overall Survival Comparing 3 mg/kg Ipilimumab with Alternative Therapies in the Management of Pretreated Patients with Unresectable Stage III or IV Melanoma. Oncologist. 2012 Oct 10. [Epub ahead of print]
   Google Scholar
• Wada R, Feng Y, Zhang N, et al. Meta-analysis of Kaplan-Meier overall survival curves from selected randomized controlled phase II/III trials in advanced melanoma. Presented at the American Conference on Pharmacometrics, 3–6 April 2011; San Diego, California, USA
   Google Scholar
• Macahilig C, Botteman M, Prinz GM, et al. Patterns of care and healthcare utilization of US advanced melanoma patients: evidence from a retrospective medical chart review. Presented at Perspectives in Melanoma XV, September 16–17, 2011; New York, NY, USA
   Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
   Google Scholar
• Annemans L, Asukai Y, Barzey V, et al. MO2 Extrapolation in oncology modelling: novel methods for novel compounds. Value Health 2011;14:A242-3
   Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009 December 20;27(36):6199-206
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. The epidemiology and clinical and demographic characteristics of advanced melanoma patients in the US: evidence from a retrospective medical chart review. [Data on file, 2011]
   Google Scholar
• Dacarbazine for Injection, USP. Hospira is based in Lake Forest, Illinois, 2007. http://www.hospira.com/Products/dacarbazine.aspx. Accessed July 17, 2012
   Google Scholar
• Quirt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007;12:1114-23
   PubMed Web of Science ®Google Scholar
• RED BOOK Drug References. Thomson Reuters Micromedex Clinical Evidence Solutions [Internet], 2010. http://thomsonreuters.com/products_services/healthcare/healthcare_products/clinical_deci_support/micromedex_clinical_evidence_sols/med_safety_solutions/red_book/
   Google Scholar
• ASP Drug Pricing Files. Centers for Medicare & Medicaid Services, 2010. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/01a19_2010aspfiles.html. Accessed October 19, 2012
   Google Scholar
• Stokes ME, Muehlenbein CE, Marciniak MD, et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009;15:669-82
   PubMed Web of Science ®Google Scholar
• Elting LS, Shih YC. The economic burden of supportive care of cancer patients. Support Care Cancer 2004;12:219-26
   PubMed Web of Science ®Google Scholar
• AHRQ. Health Care Cost & Utilization Project: Nationwide Inpatient Sample (NIS). 2005
   Google Scholar
• Beusterien KM, Szabo SM, Kotapati S, et al. Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer 2009;101:387-9
   PubMed Web of Science ®Google Scholar
• Batty AJ, Fisher D, Winn B, et al. PCN148 estimating quality of life in advanced melanoma; a comparison of standard gamble, SF-36 mapped, and Eortc QLQ-C30 mapped utilities Value in Health. 2011;14:7 p A461-2
   Google Scholar
• Davies A, Briggs A, Schneider J, et al. The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Research in Medicine February 2012;3(1):e25-e36
   Google Scholar
• Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-41
   PubMed Web of Science ®Google Scholar
• Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-42
   PubMed Web of Science ®Google Scholar
• Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 2009;27:2111-3
   PubMed Web of Science ®Google Scholar
• Becker G, Murphy K, Philipson T. The value of life near its end and terminal care. NBER Working Paper Series 2007; Working Paper 13333: published online July 13, 2012. http://www.nber.org/papers/w13333 accessed 22 October 2012
   Google Scholar
• Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-5
   PubMed Web of Science ®Google Scholar
• Seabury SA, Goldman DP, Maclean JR, et al. Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates. Health Aff (Millwood) 2012;31:691-9
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase 2 trials. Pigment Cell Melanoma Res. 2011;24(5):1072
   Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
   PubMed Web of Science ®Google Scholar
• McArthur G, Hauschild A, Robert C, et al. Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E-mutated melanoma: updated Survival results from a Phase III randomized, open-label, multicentre trial. Presented at the European Society of Clinical Oncology Conference , 23--27 September 2011; Sweden, USA
   Google Scholar